Correction to Dosing Recommendation in the Perinatal Guidelines Clarified

A recent change to the Perinatal Guidelines was further clarified on January 29, 2013. To see the clarification regarding the nevirapine (NVP) dosing recommendation in Table 9. Recommended Neonatal Dosing for Prevention of Mother-to-Child Transmission of HIV, please view the correction notice.

---

FDA Updates Complera Labeling with New Indication and Clinical Trial Information

“On January 25, 2013, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) package insert. The major changes include restricting the indication to treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL, updating the package insert with the 96 week results from the Phase 3 trials and adding a new Contraindication and new Warning and Precaution for hepatotoxicity.”

More information is available:

• FDA: Press release
• FDA: Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) label (PDF)

---

New Publications Available from CDC

The Centers for Disease Control and Prevention (CDC) recently issued the following three publications:

• HIV Surveillance Supplemental Report, Volume 18, Number 2: Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 U.S. Dependent Areas—2010. This report presents results of analyses measuring progress toward achieving objectives of the National HIV/AIDS Strategy for the United States and the Division of HIV/AIDS Prevention of CDC Strategic Plan. It is a supplement to the 2010 HIV Surveillance Report.
   
• Background Brief on the Prevention Benefits of HIV Treatment. This brief explores the concept and strategy of treatment as prevention—treating HIV-infected people with antiretroviral medications to benefit their health and also to reduce their risk of transmitting HIV to others.
   
• HIV among Pregnant Women, Infants, and Children in the United States Fact Sheet. This fact sheet describes the scope of perinatal HIV transmission in the United States, the challenges in preventing perinatal HIV transmission, and CDC efforts to address these challenges.

---